Risk factors for acute kidney injury during aminoglycoside therapy in patients with cystic fibrosis
Pediatric Nephrology, ISSN: 1432-198X, Vol: 30, Issue: 10, Page: 1879-1888
2015
- 21Citations
- 60Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations21
- Citation Indexes21
- 21
- CrossRef20
- Captures60
- Readers60
- 60
Article Description
Background: Aminoglycoside (AG) therapy is a common cause of acute kidney injury (AKI) in cystic fibrosis (CF) patients. The aim of this study was to identify factors associated with AKI during intravenous AG courses in this population. Methods: This was a matched case–control study utilizing two independent cohorts of hospitalized CF patients receiving ≥3 days of intravenous AG at Cincinnati Children’s Hospital Medical Center and Children’s of Alabama. All admissions with AKI (cases, N = 82) were matched to two randomly selected admissions without AKI (controls, N = 164) by center, gender, and age ±3 years of the case. AKI was defined as a 1.5-fold increase in the baseline serum creatinine (SCr) level or by an increase in SCr level of 0.3 mg/dL within 48 h. Admissions with AKI before day 4 or without at least weekly SCr monitoring were excluded from the analysis. Factors were compared between cases and controls using simple and multiple conditional logistic regression. Results: Multivariable analysis identified receipt of an AG within 90 days prior to admission, longer duration of AG therapy, low serum albumin, and receipt of trimethoprim/sulfamethoxazole as independent risk factors for developing AKI. Infection with Staphylococcus aureus diminished the odds of developing AKI. Conclusions: This study identifies risk factors contributing to AG-associated AKI in CF patients. These findings can be used to anticipate high-risk scenarios and limit AKI in CF patients under clinical care.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84940448735&origin=inward; http://dx.doi.org/10.1007/s00467-015-3097-3; http://www.ncbi.nlm.nih.gov/pubmed/25912993; http://link.springer.com/10.1007/s00467-015-3097-3; https://dx.doi.org/10.1007/s00467-015-3097-3; https://link.springer.com/article/10.1007/s00467-015-3097-3; https://link.springer.com/content/pdf/10.1007%2Fs00467-015-3097-3.pdf; http://link.springer.com/article/10.1007%2Fs00467-015-3097-3; http://link.springer.com/content/pdf/10.1007/s00467-015-3097-3; https://link.springer.com/content/pdf/10.1007/s00467-015-3097-3.pdf
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know